标题
Outcomes of COVID‐19 in multiple myeloma patients treated with daratumumab
作者
关键词
-
出版物
CANCER SCIENCE
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-27
DOI
10.1111/cas.16001
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Retrospective review of outcomes of Multiple Myeloma (MM) patients with COVID-19 infection (two-center study)
- (2023) Hamid Ehsan et al. Clinical Lymphoma Myeloma & Leukemia
- Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
- (2023) Evangelos Terpos et al. LEUKEMIA
- Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
- (2022) Ainsley Ryan Yan Bin Lee et al. BMJ-British Medical Journal
- Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
- (2022) Ola Blennow et al. AMERICAN JOURNAL OF HEMATOLOGY
- Risk factors for severe infection and mortality In patients with COVID ‐19 in patients with multiple myeloma and AL amyloidosis
- (2022) Matthew Ho et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cumulative Incidence and Relative Risk of Infection in Multiple Myeloma Patients Treated with anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-Analysis
- (2022) Stephanos Vassilopoulos et al. Open Forum Infectious Diseases
- Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China
- (2022) Weiping Liu et al. BONE MARROW TRANSPLANTATION
- Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
- (2021) Marta Krejci et al. ANNALS OF HEMATOLOGY
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
- (2021) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
- (2021) Soledad Henriquez et al. BLOOD
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
- (2021) Heinz Ludwig et al. Lancet Haematology
- Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China
- (2020) Fei Yu et al. MICROBES AND INFECTION
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.
- (2020) Gordon Cook et al. BRITISH JOURNAL OF HAEMATOLOGY
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
- (2020) Evangelos Terpos et al. LEUKEMIA
- COVID-19 in Immunocompromised Hosts: What We Know So Far
- (2020) Monica Fung et al. CLINICAL INFECTIOUS DISEASES
- Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
- (2020) Danai Dima et al. Cancer Management and Research
- Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
- (2020) Smith Giri et al. JAMA Oncology
- Racial and Ethnic Disparities in COVID-19–Related Infections, Hospitalizations, and Deaths
- (2020) Katherine Mackey et al. ANNALS OF INTERNAL MEDICINE
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
- (2020) Ajai Chari et al. BLOOD
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
- (2019) Hareth Nahi et al. PLoS One
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
- (2019) Maria-Victoria Mateos et al. Clinical Lymphoma Myeloma & Leukemia
- Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
- (2019) Maria-Victoria Mateos et al. LANCET
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
- (2015) Evren Alici et al. BRITISH JOURNAL OF HAEMATOLOGY
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
- (2014) C. Blimark et al. HAEMATOLOGICA
- The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
- (2010) Andrew S. Levey et al. KIDNEY INTERNATIONAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now